NOVELOS THERAPEUTICS
Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company's compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company's second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.
NOVELOS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Madison, Wisconsin, United States
Country:
United States
Website Url:
http://www.novelos.com
Total Employee:
11+
Status:
Closed
Contact:
6179646331
Total Funding:
85.8 M USD
Technology used in webpage:
SPF Google Analytics Nginx PHP CentOS Apache 2.2 DOSarrest Uniregistry
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Advantage Capital
Advantage Capital investment in Convertible Note - Novelos Therapeutics
Official Site Inspections
http://www.novelos.com
- Host name: 86-105-245-69.haip.transip.net
- IP address: 86.105.245.69
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
